论文部分内容阅读
目的:观察小牛血清去蛋白注射液辅助治疗急性前循环脑梗死的近期疗效和安全性。方法:采用随机、单盲、对照设计,96例患者随机分为对照组和观察组各48例,在常规治疗的基础上,分别静滴0.9%氯化钠注射液或小牛血清去蛋白注射液,连续21 d。分别采用美国国立卫生研究院卒中量表(NIHSS)、Barthel指数(BI)、改良Rankin量表(mRS)评价临床神经功能缺损、日常生活能力及预后功能残疾水平,记录药品不良反应。结果:治疗21 d后,两组患者NIHSS、BI及mRS评分均较治疗前有明显改善(P<0.05),且观察组上述指标改善明显优于对照组(P<0.05)。观察组临床总有效率为81.3%,明显高于对照组的62.5%(P<0.05)。用药前后两组患者血尿常规、肝肾功能、心电图等检查无异常变化,未见与小牛血清去蛋白注射液相关的不良事件。结论:小牛血清去蛋白注射液辅助治疗,对急性前循环脑梗死具有较好的治疗作用。
Objective: To observe the short-term efficacy and safety of adjuvant bovine serum albumin injection in the treatment of acute anterior circulation cerebral infarction. Methods: A randomized, single-blind, controlled design, 96 patients were randomly divided into control group and observation group of 48 cases, on the basis of routine treatment, were intravenously 0.9% sodium chloride injection or bovine serum protein injection Liquid for 21 days. The National Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI) and Modified Rankin Scale (mRS) were used to evaluate clinical neurological deficit, daily living ability and prognosis disability, and record adverse drug reactions. Results: After 21 days of treatment, NIHSS, BI and mRS scores of both groups were significantly improved compared with those before treatment (P <0.05), and the improvement of the above indexes in the observation group was obviously better than that in the control group (P <0.05). The total effective rate in observation group was 81.3%, which was significantly higher than that in control group (62.5%, P <0.05). Before and after treatment, there were no abnormal changes in blood and urine, liver and kidney function, ECG and other two groups of patients before treatment, and no adverse events related to deproteinization of bovine serum were found. Conclusion: The adjuvant therapy of deproteinization with bovine serum has a good therapeutic effect on acute anterior circulation cerebral infarction.